GET DAILY SIGNALSSilence Therapeutics (SLN) Q3 2026 Earnings: Positioned Against a +130% Premium Merck Acquisition
Key Takeaways
- Silence Therapeutics (SLN) is a clinical-stage biopharmaceutical company focused on siRNA therapies and is set to release its third quarter 2026 results in early-to-mid November.
- Consensus EPS estimates sit between -$0.11 and -$0.13, with revenue expected to stay minimal given the company’s development stage.
- Merck KGaA has agreed to acquire Silence Therapeutics for $20 per share in cash, representing roughly a 130% premium, which has anchored the stock near the deal price and redirected attention to closing timing.
- Execution on the lead candidate divesiran (SLN124) in polycythemia vera continues to be the primary long-term catalyst, with a Phase 3 program in planning.
- Investors will focus on cash position and operating expense trends to gauge how comfortably the company can fund operations until the transaction closes.
- For more on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages for a complete view of the stock.
- To discover related market opportunities, explore Trending AI Robots, which highlight automated trading strategies and signals across the market.
Why This Quarter Carries Extra Weight
Silence Therapeutics’ upcoming quarterly update arrives with the added context of the pending Merck KGaA acquisition at $20 per share in cash. As a clinical-stage firm with little product revenue, the income statement is less about near-term profits and more about insights into cash runway, R&D spending discipline, and progress on the divesiran program in polycythemia vera. Earlier quarters showed declining collaboration revenue alongside narrowing losses once milestone work wrapped up. In my view, the report will serve as a useful checkpoint on clinical execution and cost management ahead of the takeover.
What the Numbers Are Expected to Show
Analysts anticipate a modest net loss for the third quarter of 2026, with consensus EPS estimates clustered around -$0.11 to -$0.13 and revenue projected at roughly $0.1 million or lower. For comparison, the prior-year third quarter delivered an EPS of about -$0.15 and revenue near $159,000. With most collaboration revenue already recognized, top-line figures should remain minimal, so operating expenses and cash burn will be the metrics worth watching most closely. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Any commentary on Phase 3 planning for divesiran, partnership updates, or the expected close of the Merck KGaA deal will be of particular interest.
Market Sentiment Heading Into the Report
Investor focus remains centered on the agreed $20-per-share acquisition price rather than standalone operating results. With the stock trading near that level, much of the typical biotech uncertainty has been removed, which may limit earnings-related volatility. Still, any signals of delays, additional financing needs, or complications around the transaction could influence the share price, while positive clinical updates on divesiran might strengthen confidence in the deal’s logic. Regulatory timing, the chance of competing offers, and the risk that the transaction does not close remain the main factors to monitor.
Key Areas to Follow After the Release
Once the earnings are out, attention should turn to the Merck KGaA acquisition timeline and any regulatory milestones still required. Because the $20 cash payment depends on completion, the gap between the current price and the deal price is not fully locked in until closing.
The clinical path for divesiran in polycythemia vera is another important element. Earlier Phase 2 data demonstrated a notably higher response rate than placebo, and updates on Phase 3 design, enrollment plans, or regulatory feedback will be closely reviewed.
Finally, liquidity and operating expense trends deserve attention. With collaboration revenue largely concluded, the company’s ability to bridge operations to deal close hinges on controlled spending and available cash. Disclosures on cost trends and cash runway will help assess execution risk in the interim period.
Enhancing Research with AI Screening Tools
When evaluating names like this one, I often turn to Tickeron’s AI Screener to quickly scan for comparable companies and review sector trends. The tool allows filtering by fundamentals, technical patterns, and performance metrics, which helps surface relevant ideas without spending hours on manual reviews. It has become a practical part of my workflow for building context around clinical-stage biotechs and acquisition situations.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SLN in +0.20% Uptrend, growing for three consecutive days on November 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where SLN advanced for three days, in 240 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on SLN as a result. In 72 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for SLN just turned positive on October 19, 2026. Looking at past instances where SLN's MACD turned positive, the stock continued to rise in 39 of 46 cases over the following month. The odds of a continued upward trend are 85%.
SLN moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SLN crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 55 cases where SLN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
SLN broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SLN entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. SLN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (31.860) is normal, around the industry mean (2.904). P/E Ratio (-15.287) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement